I'm LongbridgeAI, I can summarize articles.Aquestive Therapeutics director Julie Krop sold 25,000 common shares on June 23, 2026, at $5.02 per share for a total of $125,392.50. The sale followed the exercise of fully vested non-qualified stock options at $0.71 per share. Consequently, Krop's directly held common stock position in the company fell to zero.
- Aquestive Therapeutics director Julie Krop reported selling 25,000 common shares on June 23, 2026 at USD 5.02. * The sale followed the exercise of a fully vested non-qualified stock option for 25,000 shares at USD 0.71. * Krop’s directly held common stock position fell to zero following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-007677), on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here